Implantable cardioverter defibrillators (ICDs)

Series
Cardiac electrophysiology
Status
Published
Date
Number of report
049

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for implantable cardioverter defibrillators.

Both Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) are considered. Use of ICD is considered for ventricular tachycardia and ventricular fibrillation.

Reimbursement analysis covers the following procedures:

  • Implantation of ICD system
  • Replacement of ICD system
  • Removal of ICD system

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of devices for implantable cardioverter defibrillators (ICDs) include:

  • Abbot Vascular (Ellipse, Fortify Assura)
  • Biotronik (Itrevia, Inventra, Intica, Inlexa)
  • Boston Scientific (Emblem MRI, Inogen Mini, Momentum, Perciva, Resonate EL, Vigilant EL, Dynagen Mini)
  • MicroPort CRM (Platinium)
  • Medtronic (Visia AF, Evera, Protecta‚ Secura, Virtuoso, Entrust, Intrinsic, Primo)

Table of content is not available at the moment. Report is still ongoing.

19

Oct 2021

In late September 2021, the Austrian version of the DRG system (LKF) 2022 model with the relevant supplementary documents was published in Austria. The document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, E-Health, and gastrointestinal area.

Read more

28

Jun 2021

In mid-June 2021, the document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, e-Health, and gastrointestinal area.

Read more

09

Nov 2020

In Sensible Care projects, the Dutch Healthcare Institute, together with other parties, is investigating the possibilities for improving care pathways for patients. As of early November 2020, there are 30 ongoing projects, including two projects for assessing knee and hip osteoarthritis treatment and medicines for castration-refractory prostate carcinoma at the final evaluation phase.

Read more

02

Dec 2019

The National disease management guideline for chronic heart failure with recommendations for diagnostics and therapy has been revised. It is now available free of charge on the internet pages of the Medical Center for Quality in Medicine.

Read more

07

Feb 2019

The report presents a summary of reimbursement situation for implantable cardioverter defibrillators. Both Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) are considered. Use of ICD is considered for ventricular tachycardia and ventricular fibrillation. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.

Read more
(we accept only company emails)